OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer
June 17, 2009 02:00 ET
|
Oxigene, Inc.
Seasoned Industry Executive With More Than 20 Years of Oncology-Focused Drug
Development Experience
WALTHAM, Mass., June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a
clinical-stage...
OXiGENE Reports Positive Data From Phase 2 Trial of ZYBRESTAT in Platinum Resistant Ovarian Cancer At the 2009 ASCO Annual Meeting
June 01, 2009 10:45 ET
|
Oxigene, Inc.
Final Data Presentation Shows 25% Confirmed Response Rate in Relapsed Patient
Population
WALTHAM, Mass., June 1, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a...
OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology
May 21, 2009 02:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Reports First Quarter 2009 Financial Results
May 11, 2009 16:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., May 11, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Announces First Quarter 2009 Earnings Conference Call and Webcast
May 04, 2009 02:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Reports Preclinical Data for OXi4503 Showing Pronounced Antitumor Activity in Animal Studies in Acute Myeloid Leukemia
April 22, 2009 02:00 ET
|
Oxigene, Inc.
OXiGENE Reports Preclinical Data for OXi4503 Showing Pronounced Antitumor
Activity in Animal Studies in Acute Myeloid Leukemia At the American
Association of Cancer Research Annual Meeting...
OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular Disrupting Agent
April 06, 2009 02:00 ET
|
Oxigene, Inc.
OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular
Disrupting Agent
WALTHAM, Mass., April 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN),
a clinical-stage...
OXiGENE Receives Qualified Opinion On Its Audited Financial Statements for 2008
March 30, 2009 16:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye...
OXiGENE Reports Fourth Quarter and Year-End 2008 Results
March 19, 2009 16:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., March 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye...
OXiGENE Announces Publication of Phase 2 Study Results With Fosbretabulin (ZYBRESTAT(tm)) Monotherapy in Anaplastic Thyroid Cancer (ATC)
March 17, 2009 02:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye...